Cargando…

Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG

Vi capsular polysaccharide (Vi) conjugate vaccines, which can prevent typhoid in infants and young children, are being developed. Comparative immunogenicity studies are facilitated by an International Standard (IS) for human anti-Vi IgG. 16/138, a pool of sera from volunteers which received either V...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rijpkema, Sjoerd, Hockley, Jason, Logan, Alastair, Rigsby, Peter, Atkinson, Eleanor, Jin, Celina, Goldblatt, David, Liang, Haoyu, Bachtiar, Novilia S., Yang, Jae Seung, Goel, Akshay, Ramasamy, Venkatesan, Pasetti, Marcela F., Pollard, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academic Press 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238147/ https://www.ncbi.nlm.nih.gov/pubmed/30201529 http://dx.doi.org/10.1016/j.biologicals.2018.09.001

Ejemplares similares

Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies
por: Rigsby, Peter, et al.
Publicado: (2020)

O-acetylation of typhoid capsular polysaccharide confers polysaccharide rigidity and immunodominance by masking additional epitopes
por: Hitri, Krisztina, et al.
Publicado: (2019)

Evidence of Extended Thermo-Stability of Typhoid Polysaccharide Conjugate Vaccines
por: Gao, Fang, et al.
Publicado: (2021)

Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals
Publicado: (1987)

Vi-specific serological correlates of protection for typhoid fever
por: Jin, Celina, et al.
Publicado: (2020)

A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2–11 years: a phase II preliminary report
por: Medise, Bernie Endyarni, et al.
Publicado: (2020)

Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever
por: Cross, Deborah L., et al.
Publicado: (2020)

Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT)
por: Lee, Eun Young, et al.
Publicado: (2020)

IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model
por: Dahora, Lindsay C., et al.
Publicado: (2019)

Head-to-Head Comparison of Humoral Immune Responses to Vi Capsular Polysaccharide and Salmonella Typhi Ty21a Typhoid Vaccines–A Randomized Trial
por: Kantele, Anu, et al.
Publicado: (2013)

Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso
por: Ouedraogo, Alphonse, et al.
Publicado: (2023)

The Distribution of Typhoid Vi Agglutinins in Normal Sera with Special Reference to Their Diagnostic Value in Typhoid Fever
por: Soman, D. W.
Publicado: (1945)

Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
por: Kim, Y. R., et al.
Publicado: (1995)

Regulation of Vi Capsular Polysaccharide Synthesis in Salmonella enterica Serotype Typhi
por: Santander, Javier M, et al.
Publicado: (2008)

Use of Typhoid Vi-Polysaccharide Vaccine as a Vaccine Probe to Delineate Clinical Criteria for Typhoid Fever
por: Islam, Md. Taufiqul, et al.
Publicado: (2020)

25 Years after Vi Typhoid Vaccine Efficacy Study, Typhoid Affects Significant Number of Population in Nepal
por: Bajracharya, Deepak, et al.
Publicado: (2014)

Establishment of the World Health Organization 2(nd) International Standard for Factor XI, Plasma, Human
por: Wilmot, Helen, et al.
Publicado: (2017)

Establishment of a WHO Reference Reagent for anti-Mullerian hormone
por: Ferguson, Jackie, et al.
Publicado: (2020)

Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011–August 2019
por: Seshadri, Srihari, et al.
Publicado: (2023)

Developing standards for the microbiome field
por: Amos, Gregory C. A., et al.
Publicado: (2020)

Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study
por: Bilcke, Joke, et al.
Publicado: (2019)

Adsorption of Vi Capsular Antigen of Salmonella Typhi in Chitosan–Poly (Methacrylic Acid) Nanoparticles
por: da Silva, Raimundo Lopes, et al.
Publicado: (2019)

Investigation of core machinery for biosynthesis of Vi antigen capsular polysaccharides in Gram-negative bacteria
por: Wear, Samantha S., et al.
Publicado: (2021)

The establishment of sub-strain specific WHO Reference Reagents for BCG vaccine
por: Dagg, Belinda, et al.
Publicado: (2014)

Establishment of the World Health Organization First International Standard for Factor XII, Plasma, Human
por: Wilmot, Helen V., et al.
Publicado: (2018)

Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8–9 months-old Indian children
por: Vadrevu, Krishna Mohan, et al.
Publicado: (2022)

Re-evaluating herd protection by Vi typhoid vaccine in a cluster randomized trial
por: Ali, Mohammad, et al.
Publicado: (2019)

Typhoid—From Past to Future
por: Kirchhelle, Claas, et al.
Publicado: (2019)

The Vi Capsular Polysaccharide Enables Salmonella enterica Serovar Typhi to Evade Microbe-Guided Neutrophil Chemotaxis
por: Wangdi, Tamding, et al.
Publicado: (2014)

Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial
por: Sirima, Sodiomon B., et al.
Publicado: (2021)

The Time is Now to Control Typhoid
por: Pollard, Andrew J, et al.
Publicado: (2019)

MyD88-dependent pro-inflammatory activity in Vi polysaccharide vaccine against typhoid promotes Ab switching to IgG
por: Garg, Rohini, et al.
Publicado: (2015)

The Lack of Natural IgM Increases Susceptibility and Impairs Anti-Vi Polysaccharide IgG Responses in a Mouse Model of Typhoid
por: Alugupalli, Akhil S., et al.
Publicado: (2022)

Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model
por: Gibani, Malick M., et al.
Publicado: (2019)

Recent Developments in Enteric Bacterial Vaccines
por: Rijpkema, Sjoerd, et al.
Publicado: (2021)

A Turning Point in Typhoid Control
por: Bentsi-Enchill, Adwoa D, et al.
Publicado: (2018)

Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial
por: Jin, Celina, et al.
Publicado: (2017)

Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine
por: Medise, Bernie Endyarni, et al.
Publicado: (2019)

Molecular correlates of vaccine-induced protection against typhoid fever
por: Zhu, Henderson, et al.
Publicado: (2023)

Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial
por: Theiss-Nyland, Katherine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oqo9v04vmp7oam7h1s7cec0lic